Literature DB >> 28178400

Levels of l-arginine and l-citrulline in patients with erectile dysfunction of different etiology.

A Barassi1, M M Corsi Romanelli2,3, R Pezzilli4, C A L Damele1, L Vaccalluzzo5, G Goi6, N Papini7, G M Colpi5, L Massaccesi6, G V Melzi d'Eril1.   

Abstract

Nitric oxide is a physiologic signal essential to penile erection. l-citrulline (l-Cit) is converted into l-arginine (l-Arg), the precursor from which nitric oxide is generated. The level of l-Arg and l-Cit in the field of male sexual function remains relatively underexplored. The aim of the study was to evaluate the level of serum l-Arg and of l-Cit in a group of patients with erectile dysfunction. Diagnosis and severity of erectile dysfunction was based on the IIEF-5 and its etiology was classified as arteriogenic (A-ED), borderline (BL-ED), and non-arteriogenic (NA-ED) with penile echo-color-Doppler in basal condition and after intracaversous injection of prostaglandin E1. Serum l-Arg and l-Cit concentrations were measured by a cation-exchange chromatography system. l-Arg and l-Cit levels of men with A-ED were compared with those of male with BL-ED and NA-ED. Median level of l-Arg and l-Cit in 122 erectile dysfunction patients (41 A-ED, 23 ED-BL, 58 NA-ED) was 82.7 and 35.4 μmol/L, respectively. l-Arg and l-Cit levels in control patients were not significantly different (p = 0.233 and p = 0.561, respectively) than in total erectile dysfunction patients. l-Arg and l-Cit levels in control patients were significantly higher (p < 0.001 and p < 0.018, respectively) than in A-ED patients, but no difference (p > 0.50) was observed in controls and in both BL-ED and NA-ED patients. Patients with severe/complete-erectile dysfunction (IIEF-5 < 10) had l-Arg or l-Cit level significantly lower (-17%, p < 0.03; -13%, p < 0.04) and were more frequent (p < 0.01 and p < 0.04) under the respective median level (82.7 and 35.4 μmol/L) than those with mild-erectile dysfunction (IIEF-5 = 16-20). l-Arg and l-Cit levels in A-ED were significantly lower (p < 0.007 and p < 0.001, respectively) than in NA-ED patients. Penile echo-color-Doppler revealed that A-ED (peak systolic velocity ≤ 25 cm/sec) was more frequent in men with l-Arg under 82.7 μmol/L or l-Cit under 35.4 μmol/L and in the same population, the median peak systolic velocity values were lower in l-Arg deficient (29 vs. 35; p < 0.04) and also in l-Cit deficient (31 vs. 33, p > 0.3) but without reaching the statistical significance. Our study shows that a significant proportion of erectile dysfunction patients have low l-Arg or l-Cit level and that this condition is more frequent in patients with arteriogenic etiology. Low levels of these nitric oxide synthase substrates might increase the erectile dysfunction risk by reducing the concentration of nitric oxide.
© 2017 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  erectile dysfunction; l-arginine; l-citrulline

Mesh:

Substances:

Year:  2017        PMID: 28178400     DOI: 10.1111/andr.12293

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  4 in total

1.  Serum Arginase II level can be a novel indicator for erectile dysfunction in patients with vasculogenic erectile dysfunction: a comparative study.

Authors:  Abdel Shakour Abdel Hafez Abdel Wahed; Mohamed Abdel Mawgood Amer; Nagah Mohamed Abou Mohamed; Mohamed Ismael Mobasher; Hassan Mamdouh; Sameh Fayek GamalEl Din; Mohammed Said ElSheemy
Journal:  Int Urol Nephrol       Date:  2018-06-28       Impact factor: 2.370

Review 2.  Alternative Treatment for Erectile Dysfunction: a Growing Arsenal in Men's Health.

Authors:  Wade Muncey; Nicholas Sellke; Tyler Kim; Kirtishri Mishra; Nannan Thirumavalavan; Aram Loeb
Journal:  Curr Urol Rep       Date:  2021-01-09       Impact factor: 3.092

3.  Long-term high-dose L-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial.

Authors:  D Menafra; C de Angelis; F Garifalos; M Mazzella; G Galdiero; M Piscopo; M Castoro; N Verde; C Pivonello; C Simeoli; R S Auriemma; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2022-01-01       Impact factor: 4.256

4.  The Daily Therapy With L-Arginine 2,500 mg and Tadalafil 5 mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre Study.

Authors:  Luigi Gallo; Stefano Pecoraro; Pasquale Sarnacchiaro; Mauro Silvani; Gabriele Antonini
Journal:  Sex Med       Date:  2020-03-16       Impact factor: 2.491

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.